About the Authors
- Ping He
-
Affiliation Center for Advanced Therapeutic Strategies of Brain Disorders, Roskamp Institute, Sarasota, Florida, United States of America
- Xin Cheng
-
Affiliation Department of Neurology and Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China
- Matthias Staufenbiel
-
Affiliation Novartis Pharm Ltd., Nervous System Research, Basel, Switzerland
- Rena Li
-
Affiliation Center for Hormone Advanced Science and Education, Roskamp Institute, Sarasota, Florida, United States of America
- Yong Shen
-
* E-mail: yshen@rfdn.org
Affiliations Center for Advanced Therapeutic Strategies of Brain Disorders, Roskamp Institute, Sarasota, Florida, United States of America, Department of Neurology and Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China
Competing Interests
Matthias Staufenbiel is employed by Novartis Pharm Ltd. APP23 transgenic (20 males and 20 females in each age group) and non-transgenic wild type (20 males and 20 females in each age group) genotypes in our experiment are on the C57BL/6 background, which were provided by Novartis Institute for Biomedical Research. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Examined and analyzed the data: PH YS. Conceived and designed the experiments: YS RL. Performed the experiments: PH XC. Contributed reagents/materials/analysis tools: MS. Wrote the paper: PH YS RL.